These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 12835674

  • 1. Rethinking clinical trials for cytostatic drugs.
    Millar AW, Lynch KP.
    Nat Rev Cancer; 2003 Jul; 3(7):540-5. PubMed ID: 12835674
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A, Wheeler C, Barge A.
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [Abstract] [Full Text] [Related]

  • 4. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
    Calvert AH, Plummer R.
    Clin Cancer Res; 2008 Jun 15; 14(12):3664-9. PubMed ID: 18559580
    [Abstract] [Full Text] [Related]

  • 5. Cancer clinical trials: development and implementation.
    Vail DM.
    Vet Clin North Am Small Anim Pract; 2007 Nov 15; 37(6):1033-57; v. PubMed ID: 17950881
    [Abstract] [Full Text] [Related]

  • 6. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
    El-Maraghi RH, Eisenhauer EA.
    J Clin Oncol; 2008 Mar 10; 26(8):1346-54. PubMed ID: 18285606
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Endpoints for agents that slow tumor growth.
    Yu RX, Holmgren E.
    Contemp Clin Trials; 2007 Jan 10; 28(1):18-24. PubMed ID: 16829208
    [Abstract] [Full Text] [Related]

  • 10. Adaptive design may hasten clinical trials.
    Schmidt C.
    J Natl Cancer Inst; 2007 Jan 17; 99(2):108-9. PubMed ID: 17227993
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ, Panel of Experts in HCC-Design Clinical Trials.
    J Natl Cancer Inst; 2008 May 21; 100(10):698-711. PubMed ID: 18477802
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase 0 clinical trials in oncology: an exploratory methodology for constructing a study with patients undergoing surgery for metastatic disease.
    Pocard M, Soria JC, Aldaz-Carroll L, Bellet D.
    J Clin Oncol; 2010 Oct 20; 28(30):4551-3. PubMed ID: 20837954
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Improving the evaluation of new cancer treatments: challenges and opportunities.
    Rothenberg ML, Carbone DP, Johnson DH.
    Nat Rev Cancer; 2003 Apr 20; 3(4):303-9. PubMed ID: 12671669
    [Abstract] [Full Text] [Related]

  • 19. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH.
    Cancer Chemother Pharmacol; 2009 Mar 20; 63(4):703-9. PubMed ID: 18615251
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.